The standardized uptake value calculated from 111In-ibritumomab tiuxetan single-photon emission computed tomography/computed tomography is a useful predictor of the clinical response in patients treated by 90Y- ibritumomab tiuxetan therapy
| Autor: | Ayaka Kume, Akira Toriihara, Naoki Harata, Ryo Shimizu, Hiroaki Tanaka, Jun Isogai |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cytopenia
medicine.diagnostic_test business.industry medicine.medical_treatment Therapeutic effect Ibritumomab tiuxetan Retrospective cohort study Standardized uptake value General Medicine Single-photon emission computed tomography medicine.disease 030218 nuclear medicine & medical imaging Lymphoma 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Radioimmunotherapy medicine Nuclear medicine business medicine.drug |
| Zdroj: | Journal of Clinical and Experimental Hematopathology. 61:29-34 |
| ISSN: | 1880-9952 1346-4280 |
| DOI: | 10.3960/jslrt.20055 |
| Popis: | 90Y-Ibritumomab tiuxetan (IT) therapy is a radioimmunotherapy for indolent B-cell lymphoma. Several predictors of insufficient therapeutic effects have been reported. We performed a retrospective study at a single institute to investigate whether 111In SPECT/CT can predict the therapeutic effects and grade of cytopenia due to 90Y-IT therapy. We enrolled 16 consecutive patients who underwent 90Y-IT therapy, including 15 who underwent 111In-IT SPECT/CT. After 90Y-IT therapy, there were 4 patients in complete remission in whom the lesion SUVmax on 111In-IT SPECT/CT and soluble IL-2 receptor were significantly lower than those of the other patients (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|